Literature DB >> 30333301

Injury promotes sarcoma development in a genetically and temporally restricted manner.

David Van Mater1, Eric Xu2, Anupama Reddy3, Leonor Añó4, Mohit Sachdeva2, Wesley Huang2, Nerissa Williams2, Yan Ma2, Cassandra Love3, Lanie Happ3, Sandeep Dave3, David G Kirsch2,4.   

Abstract

Cancer results from the accumulation of genetic mutations in a susceptible cell of origin. We and others have also shown that injury promotes sarcoma development, but how injury cooperates with genetic mutations at the earliest stages of tumor formation is not known. Here, we utilized dual recombinase technology to dissect the complex interplay of the timing of KrasG12D activation, p53 deletion, and muscle injury in sarcomagenesis using a primary mouse model of soft tissue sarcoma. When mutations in oncogenic Kras and p53 are separated by 3 weeks, few sarcomas develop without injury. However, the transformation potential of these tumor-initiating cells can be unmasked by muscle injury. In the absence of Kras mutations, injury of the muscle with global deletion of p53 results in sarcomas with amplification of chromosomal regions encompassing the Met or Yap1 gene. These findings demonstrate a complex interplay between the timing of genetic mutations and perturbations in the tumor microenvironment, which provides insight into the earliest stages of sarcoma development.

Entities:  

Keywords:  Cancer; Mouse models; Oncology

Mesh:

Substances:

Year:  2018        PMID: 30333301      PMCID: PMC6237448          DOI: 10.1172/jci.insight.123687

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  31 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Methods to generate genetically engineered mouse models of soft tissue sarcoma.

Authors:  Rebecca D Dodd; Leonor Añó; Jordan M Blum; Zhizhong Li; David Van Mater; David G Kirsch
Journal:  Methods Mol Biol       Date:  2015

3.  Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta.

Authors:  M H Sieweke; N L Thompson; M B Sporn; M J Bissell
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

4.  Atm deletion with dual recombinase technology preferentially radiosensitizes tumor endothelium.

Authors:  Everett J Moding; Chang-Lung Lee; Katherine D Castle; Patrick Oh; Lan Mao; Shan Zha; Hooney D Min; Yan Ma; Shiva Das; David G Kirsch
Journal:  J Clin Invest       Date:  2014-07-18       Impact factor: 14.808

Review 5.  Soft tissue sarcomas of adults: state of the translational science.

Authors:  Ernest C Borden; Laurence H Baker; Robert S Bell; Vivien Bramwell; George D Demetri; Burton L Eisenberg; Christopher D M Fletcher; Jonathan A Fletcher; Marc Ladanyi; Paul Meltzer; Brian O'Sullivan; David R Parkinson; Peter W T Pisters; Scott Saxman; Samuel Singer; Murali Sundaram; Allan T van Oosterom; Jaap Verweij; Jill Waalen; Sharon W Weiss; Murray F Brennan
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

6.  Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis.

Authors:  Nathan P Young; Denise Crowley; Tyler Jacks
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

7.  Generation of primary tumors with Flp recombinase in FRT-flanked p53 mice.

Authors:  Chang-Lung Lee; Everett J Moding; Xiaofang Huang; Yifan Li; Loretta Z Woodlief; Rafaela C Rodrigues; Yan Ma; David G Kirsch
Journal:  Dis Model Mech       Date:  2011-12-22       Impact factor: 5.758

8.  High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells.

Authors:  Christopher S Raymond; Philippe Soriano
Journal:  PLoS One       Date:  2007-01-17       Impact factor: 3.240

9.  Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma.

Authors:  Jianguo Huang; Mark Chen; Melodi Javid Whitley; Hsuan-Cheng Kuo; Eric S Xu; Andrea Walens; Yvonne M Mowery; David Van Mater; William C Eward; Diana M Cardona; Lixia Luo; Yan Ma; Omar M Lopez; Christopher E Nelson; Jacqueline N Robinson-Hamm; Anupama Reddy; Sandeep S Dave; Charles A Gersbach; Rebecca D Dodd; David G Kirsch
Journal:  Nat Commun       Date:  2017-07-10       Impact factor: 14.919

10.  TAZ and YAP are frequently activated oncoproteins in sarcomas.

Authors:  Colleen A Fullenkamp; Sarah L Hall; Omar I Jaber; Brittany L Pakalniskis; Erica C Savage; Johanna M Savage; Georgina K Ofori-Amanfo; Allyn M Lambertz; Stephanie D Ivins; Christopher S Stipp; Benjamin J Miller; Mohammed M Milhem; Munir R Tanas
Journal:  Oncotarget       Date:  2016-05-24
View more
  4 in total

1.  Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma.

Authors:  Chang-Lung Lee; Yvonne M Mowery; Andrea R Daniel; Dadong Zhang; Alexander B Sibley; Joe R Delaney; Amy J Wisdom; Xiaodi Qin; Xi Wang; Isibel Caraballo; Jeremy Gresham; Lixia Luo; David Van Mater; Kouros Owzar; David G Kirsch
Journal:  JCI Insight       Date:  2019-07-11

2.  Fusion-mediated chromosomal instability promotes aneuploidy patterns that resemble human tumors.

Authors:  Lucile Delespaul; Candice Merle; Tom Lesluyes; Pauline Lagarde; Sophie Le Guellec; Gaëlle Pérot; Jessica Baud; Martina Carlotti; Coralie Danet; Murielle Fèvre; Benoit Rousseau; Stéphanie Durrieu; Martin Teichmann; Jean-Michel Coindre; Lydia Lartigue; Frédéric Chibon
Journal:  Oncogene       Date:  2019-07-03       Impact factor: 9.867

3.  Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1.

Authors:  Huan-Tian Zhang; Tao Gui; Ri-Xu Liu; Kui-Leung Tong; Chong-Jie Wu; Zhenyan Li; Xun Huang; Qiu-Tong Xu; Jie Yang; Wang Tang; Yuan Sang; Wanting Liu; Ning Liu; Ryan D Ross; Qing-Yu He; Zhen-Gang Zha
Journal:  Cell Death Dis       Date:  2021-01-25       Impact factor: 8.469

4.  Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models.

Authors:  Wade R Gutierrez; Amanda Scherer; Gavin R McGivney; Qierra R Brockman; Vickie Knepper-Adrian; Emily A Laverty; Grace A Roughton; Rebecca D Dodd
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.